Vanqua Bio Inc. has synthesized C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, and cardiovascular, inflammatory and neurological disorders.